Omnicell, Inc., a leader in the transformation of pharmacy and nursing care delivery, has updated its second quarter and full year 2025 financial outlook. The updates are influenced by recent reductions in U.S. tariff rates on imports from China, which are expected to improve the company's profitability by reducing supply chain impacts. The company has adjusted its Non-GAAP EBITDA to a range of $22 million to $30 million for the second quarter and $100 million to $145 million for the full year. Non-GAAP earnings per share projections have also been updated to range between $0.19 and $0.32 for the second quarter and $1.00 to $1.65 for the full year. In addition, Omnicell has announced a new $75 million stock repurchase program, reflecting its strong free cash flow and confidence in delivering innovative medication management solutions. This new program supplements an existing $50 million repurchase program approved in 2016. The guidance provided is based on current information, and the company has stated it will not update this guidance publicly unless required by law.